Proceedings of the National Academy of Sciences · 2010 · 87 citations · 41 references
Life SciencesImmunologyOncologyGlycobiologyImmunotherapyMonoclonal AntibodiesAntibody CharacterizationAntibody StructureAntibody-antigen RecognitionCancer ImmunotherapyTumor AntigensTumor-associated AntigensAntibody Glycan RecognitionConformational Epitope BindingGlycan Recognition By AntibodiesGlycan Recognition In CancerMonoclonal Antibody InteractionsMonoclonal Antibody RecognitionStructural Basis Of SpecificityTumor-associated Carbohydrate Antigens
Aberrant glycosylation, especially the Tn antigen, is a frequent cancer hallmark, yet its presence on non‑malignant tissues limits its tumor specificity. The study reports the structural basis for how monoclonal antibody 237mAb binds a truly tumor‑specific Tn‑containing glycopeptide. 237mAb binds the Tn glycopeptide by a germ‑line‑encoded pocket that envelopes the carbohydrate while engaging the peptide in a shallow groove, yielding tumor specificity without cross‑reactivity to unglycosylated peptide or free glycan.
Aberrant glycosylation and the overexpression of certain carbohydrate moieties is a consistent feature of cancers, and tumor-associated oligosaccharides are actively investigated as targets for immunotherapy. One of the most common aberrations in glycosylation patterns is the presentation of a single O-linked N-acetylgalactosamine on a threonine or serine residue known as the "Tn antigen." Whereas the ubiquitous nature of Tn antigens on cancers has made them a natural focus of vaccine research, such carbohydrate moieties are not always tumor-specific and have been observed on embryonic and nonmalignant adult tissue. Here we report the structural basis of binding of a complex of a monoclonal antibody (237mAb) with a truly tumor-specific glycopeptide containing the Tn antigen. In contrast to glycopeptide-specific antibodies in complex with simple peptides, 237mAb does not recognize a conformational epitope induced in the peptide by sugar substitution. Instead, 237mAb uses a pocket coded by germ-line genes to completely envelope the carbohydrate moiety itself while interacting with the peptide moiety in a shallow groove. Thus, 237mAb achieves its striking tumor specificity, with no observed physiological cross-reactivity to the unglycosylated peptide or the free glycan, by a combination of multiple weak but specific interactions to both the peptide and to the glycan portions of the antigen.
41
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Structural Insights into the Evolution of an Antibody Combining Site
Gary J. Wedemayer, Phillip A. Patten, Leo H. Wang et al. · Science · 1997 · 553 citations
Pharmacy, Biochemistry, Immunology +17